Bad News not only for Roche, but for Psychiatry

Last Tuesday, on January 21st, 2014, the Swiss pharmaceutical company Roche published a press release on the first results of two Phase III studies with its glycine transporter inhibitor bitopertin (RG-1678) in patients with schizophrenia. Continue reading

Antipsychotics: Less is Again More

It is now clinical standard and recommended by all treatment guidelines to continue an antipsychotic maintenance therapy for at least 12 months after remission of the first psychotic episode. Numerous studies have shown that the risk of relapse is significantly increased, if a drug treatment is terminated prematurely. In the September issue of JAMA Psychiatry Lex Wunderink and colleagues from the Netherlands, however, question these treatment habits at least in part (Wunderink et al., JAMA Psychiatry 2013; 70: 913-920). Continue reading

The Most Transformative Drugs of the Past 25 Years

In the June issue of Nature Reviews Drug Discovery Aaron Kesselheim and Jerry Avorn from Harvard Medical School in Boston, Massachusetts, published the results of their survey among physicians for the most transformative drugs of the past 25 years (Kesselheim und Avorn, Nat Rev Drug Discov 2013, 12: 425-431). Continue reading

Drug Prescription Report 2012: Antipsychotics

I have not yet covered the antipsychotics in my reporting on the drug prescription report, I want to catch this today. This important group of drugs is discussed in the chapter “psychotropic drugs”. As mentioned already in my post from November 9th, 2012, the quality of the chapter suffers greatly from the superficial and unscientific representation of the two authors Lohse and Müller-Oerlinghausen. I will essentially limit this post on the discussion of the numbers rather than discuss the limitations of the chapter again. Continue reading